Superbranche
Magnetic nanoparticles for focused-hyperthermia cancer treatment and imaging, developed for research and biotech partners
Highlights
- New on EvolcAdded 2026-11-11
About Superbranche
Superbranche develops nanoparticle-based approaches to cancer treatment that rely on physics rather than biology. Its SUPERSPIO nanoparticles are activated by focused magnetic hyperthermia to destroy tumour cells, and they can be imaged by MRI and magnetic particle imaging (MPI) to track them in the body. The technology also supports in vivo tracking of cell-based and other advanced therapies.
The company works with research institutes and industrial players internationally. Its SUPERSPIO20 nanoparticles are being tested in several application contexts. Its customers are research and biotech partners rather than end patients.
Superbranche was founded in 2019 and originates from a CNRS mixed research unit at the University of Strasbourg, in partnership with hospitals. It is headquartered in Strasbourg and is building a GMP-standard pilot plant in Sélestat, designed to produce 1 to 4 kg of nanoparticles per year. The company reports 10 years of research, 5 patents and 4 preclinical proofs of concept, and a EUR 13 million fundraising in February 2025.
Product: SUPERSPIO nanoparticles for magnetic hyperthermia cancer therapy, with MRI and magnetic particle imaging tracking.
Jobs at Superbranche
More biotech & pharma companies
Synaxys
Preclinical neuroscience assays and human neuronal models for pharmaceutical and research organizationsNew on EvolcSyndivia
Develops antibody-drug conjugate candidates and hinge-specific conjugation technology for cancer treatmentNew on EvolcSynthenova
Custom organic chemistry synthesis and R&D contracts for biotech, pharma, cosmetic and chemical companiesNew on EvolcSyntivia
Cosmetic R&D and in vitro testing services for beauty and personal-care companiesNew on EvolcTamrisa
Develops antibiotics and supplies established anti-infective medicines for patients and healthcare marketsYoung companyNew on EvolcTarian Pharma
Developing a topical treatment to prevent skin toxicities in patients receiving cancer therapiesNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content delivery
- CloudflareHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Content management
- WordPressHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Forms
- Gravity FormsHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- jQueryHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Hosting
- ApacheHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.